European Heart Rhythm Association (ehra)/heart Rhythm Society (hrs)/asia Pacific Heart Rhythm Society (aphrs)/latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases
Arthur A.M. Wilde,Christopher Semsarian,Manlio F. Márquez,Alireza Sepehri Shamloo,Michael J. Ackerman,Euan A. Ashley,Eduardo Back Sternick,Héctor Barajas-Martinez,Elijah R. Behr,Connie R. Bezzina,Jeroen Breckpot,P. Charron,Priya Chockalingam,Lia Crotti,Michael H. Gollob,Steven A. Lubitz,Naomasa Makita,Seiko Ohno,Martín Ortiz‐Genga,Luciana Sacilotto,Eric Schulze‐Bahr,Wataru Shimizu,Nona Sotoodehnia,Rafik Tadros,James S. Ware,David S. Winlaw,Elizabeth S. Kaufman,Takeshi Aiba,A Bollmann,Jong‐Il Choi,Aarti Dalal,Darrieux Francisco,John R. Giudicessi,Mariana Guerchicoff,Kui Hong,Andrew D. Krahn,Ciorsti MacIntyre,Judith A. Mackall,Lluís Mont,Carlo Napolitano,Juan Pablo Ochoa,Petr Peichl,Alexandre C. Pereira,Peter J. Schwartz,Jon Skinner,Christoph Stellbrink,Jacob Tfelt‐Hansen,Thomas Deneke
DOI: https://doi.org/10.1016/j.hrthm.2022.03.1225
IF: 6.779
2022-01-01
Heart Rhythm
Abstract:Genetic testing has advanced significantly since the publication of the 2011 HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies.1Ackerman M.J. Priori S.G. Willems S. Berul C. Brugada R. Calkins H. et al.European Heart Rhythm Association (EHRA)HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).Europace. 2011; 13: 1077-1109Crossref PubMed Scopus (559) Google Scholar In addition to single-gene testing, there is now the ability to perform whole-exome sequencing (WES) and whole-genome sequencing (WGS). There is growing appreciation of oligogenic disorders,2Schwartz P.J. Crotti L. George Jr., A.L. Modifier genes for sudden cardiac death.Eur Heart J. 2018; 39: 3925-3931PubMed Google Scholar,3Walsh R. Tadros R. Bezzina C.R. When genetic burden reaches threshold.Eur Heart J. 2020; 41: 3849-3855Crossref PubMed Scopus (11) Google Scholar the role of modifier genes,2Schwartz P.J. Crotti L. George Jr., A.L. Modifier genes for sudden cardiac death.Eur Heart J. 2018; 39: 3925-3931PubMed Google Scholar and the use of genetic testing for risk stratification, even in common cardiac diseases such as coronary artery disease or atrial fibrillation (AFib), including a proposal for a score awaiting validation.4Khera A.V. Chaffin M. Aragam K.G. Haas M.E. Roselli C. Choi S.H. et al.Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.Nat Genet. 2018; 50: 1219-1224Crossref PubMed Scopus (992) Google Scholar This document reviews the state of genetic testing at the present time, and addresses the questions of what tests to perform and when to perform them. It should be noted that, as articulated in a 1999 Task Force Document by the European Society of Cardiology (ESC) on the legal value of medical guidelines,5Schwartz P.J. Breithardt G. Howard A.J. Julian D.G. Rehnqvist Ahlberg N. Task Force Report: the legal implications of medical guidelines—a Task Force of the European Society of Cardiology.Eur Heart J. 1999; 20: 1152-1157Crossref PubMed Scopus (0) Google Scholar ‘The guidelines from an international organization, such as the ESC, have no specific legal territory and have no legally enforcing character. Nonetheless, in so far as they represent the state-of-the-art, they may be used as indicating deviation from evidence-based medicine in cases of questioned liability’. In the case of potentially lethal and treatable conditions such as catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS), it is the responsibility of the physician, preferably in conjunction with an expert genetics team, to communicate to the patient/family the critical importance of family screening, whether this be facilitated by cascade genetic testing or by broader clinical family screening. The writing committee included chairs and representatives nominated and approved by European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS). Chairs and authors had no relevant relationship with industry (RWI). Details are available in Supplementary material online. Writing committee members were assigned topics, compiled tables of recommendations supported by appropriate text and references, and attended periodic virtual meetings. Writing committee members without relevant RWI drafted recommendations. In the arena of genetic testing, there are few if any randomized trials to provide the strongest level of scientific evidence. Recommendations were associated with a green heart symbol (‘should do this’) if supported by at least strong observational evidence and author consensus. A yellow heart (‘may do this’) was used if there was some evidence and general agreement. A red heart (‘do not do this’) indicated evidence or general agreement not to perform this testing (Table 1). Writing committee consensus of 80% was required. The recommendations were approved by an average of 93% of the writing committee members.Table 1Scientific rationale of consensus statementsaThe categorization for our consensus document should not be considered directly similar to the one used for official society guideline recommendations which apply a classification (I–III) and level of evidence (A, B, and C) to recommendations.Definitions related to a treatment or procedureConsensus statement instructionSymbolSupported by strong observational evidence and authors’ consensus‘Should do this’Some evidence and general agreement favour the usefulness/efficacy of a test‘May do this’There is evidence or general agreement not to recommend a test‘Do not do this’a The categorization for our consensus document should not be considered directly similar to the one used for official society guideline recommendations which apply a classification (I–III) and level of evidence (A, B, and C) to recommendations. Open table in a new tab After review by the writing committee, the recommendations were opened for public comment. The document was then reviewed by the scientific documents committees of EHRA, HRS, APHRS, and LAHRS. After revision, the document was sent to external reviewers nominated by the participating societies. After further revision, the document was endorsed by the collaborating societies and presented for publication. This document addresses essential principles of genetic testing including modes of inheritance, different testing methodologies, and interpretation of variants. Additionally, the document presents the state of genetic testing for inherited arrhythmia syndromes, cardiomyopathies, sudden cardiac death (SCD), congenital heart disease (CHD), coronary artery disease, and heart failure. A discussion of aortopathies and hyperlipidaemia is beyond the scope of this document. The authors discuss diagnostic, prognostic, and therapeutic implications of genetic testing in each of these syndromes, as far as these are known. The writing committee recognizes that the feasibility of genomic testing by gene panel testing or by WES or WGS depends on the availability of genomic technology and on regional reimbursement policy. Therefore, the recommendation ‘should do this’ can be read as ‘should do this when available’. Table 2 lists previous guidelines and consensus statements that are considered pertinent for this document as they all include relevant information for the diagnosis of patients with inherited cardiovascular conditions (ICCs) and the need for genetic testing. The terms and abbreviations used in consensus statement are summarized in Table 3.Table 2Relevant clinical practice documents or guidelinesTitlePublication yearConsensus documents/guidelines of scientific societies APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families6Stiles M.K. Wilde A.A.M. Abrams D.J. Ackerman M.J. Albert C.M. Behr E.R. et al.2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families.Heart Rhythm. 2021; 18: e1-50Abstract Full Text Full Text PDF PubMed Google Scholar2021 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias7Cronin E.M. Bogun F.M. Maury P. Peichl P. Chen M. Namboodiri N. et al.2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary.J Arrhythm. 2020; 36: 1-58Crossref PubMed Scopus (8) Google Scholar2020 Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association8Musunuru K. Hershberger R.E. Day S.M. Klinedinst N.J. Landstrom A.P. Parikh V.N. et al.American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical CardiologyGenetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association.Circ Genom Precis Med. 2020; 13e000067Crossref Scopus (65) Google Scholar2020 European Recommendations Integrating Genetic Testing into Multidisciplinary Management of Sudden Cardiac Death9Fellmann F. van El C.G. Charron P. Michaud K. Howard H.C. Boers S.N. et al.on behalf of European Society of Human Genetics, European Council of Legal Medicine, European Society of Cardiology working group on myocardial and pericardial diseases, European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Association for European Cardiovascular PathologyEuropean recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death.Eur J Hum Genet. 2019; 27: 1763-1773Crossref PubMed Scopus (32) Google Scholar2019 Pre-participation Cardiovascular Evaluation for Athletic Participants to Prevent Sudden Death: Position Paper from the EHRA and the EACPR, Branches of the ESC22Mont L. Pelliccia A. Sharma S. Biffi A. Borjesson M.B. Terradellas J. et al.ReviewersPre-participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE.Eur J Prev Cardiol. 2017; 24: 41-69Crossref PubMed Scopus (129) Google Scholar2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy11Towbin J.A. McKenna W.J. Abrams D.J. Ackerman M.J. Calkins H. Darrieux F.C.C. et al.2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: executive summary.Heart Rhythm. 2019; 16: e373-407Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar2019 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death12Al-Khatib S.M. Stevenson W.G. Ackerman M.J. Bryant W.J. Callans D.J. Curtis A.B. et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart Rhythm. 2018; 15: e190-252Abstract Full Text Full Text PDF PubMed Scopus (291) Google Scholar2017 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death13Priori S.G. Blomström-Lundqvist C. Mazzanti A. Blom N. Borggrefe M. Camm J. et al.2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC).Eur Heart J. 2015; 36: 2793-2867Crossref PubMed Scopus (2195) Google Scholar2015 EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias14Pedersen C.T. Kay G.N. Kalman J. Borggrefe M. Della-Bella P. Dickfeld T. et al.EP-Europace,UKEHRA/HRS/APHRS expert consensus on ventricular arrhythmias.Heart Rhythm. 2014; 11: e166-e196Abstract Full Text Full Text PDF PubMed Google Scholar2014 HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes15Priori S.G. Wilde A.A. Horie M. Cho Y. Behr E.R. Berul C. et al.HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.Heart Rhythm. 2013; 10: 1932-1963Abstract Full Text Full Text PDF PubMed Scopus (1145) Google Scholar2013 HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies1Ackerman M.J. Priori S.G. Willems S. Berul C. Brugada R. Calkins H. et al.European Heart Rhythm Association (EHRA)HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).Europace. 2011; 13: 1077-1109Crossref PubMed Scopus (559) Google Scholar2011 Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases16Charron P. Arad M. Arbustini E. Basso C. Bilinska Z. Elliott P. et al.Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur Heart J. 2010; 31: 2715-2726Crossref PubMed Scopus (306) Google Scholar2010NIH-Clinical Genome Resource Consortium (ClinGen) documents A Multi-Centred, Evidence-Based Evaluation of Gene Validity in Sudden Arrhythmic Death Syndromes: CPVT and The Short QT Syndrome17Walsh R. Adler A. Amin A.S. Abiusi E. Care M. Bikker H. et al.A multi-centred, evidence-based evaluation of gene validity in sudden arrhythmic death syndromes: CPVT and the short QT syndrome.Eur Heart J. 2021; https://doi.org/10.1093/eurheartj/ehab687Crossref Scopus (5) Google Scholar2022 International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework18James C.A. Jongbloed J.D.H. Hershberger R.E. Morales A. Judge D.P. Syrris P. et al.International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework.Circ Genom Precis Med. 2021; 14e003273Crossref Scopus (22) Google Scholar2021 Evidence-Based Assessment of Genes in Dilated Cardiomyopathy19Jordan E. Peterson L. Ai T. Asatryan B. Bronicki L. Brown E. et al.Evidence-based assessment of genes in dilated cardiomyopathy.Circulation. 2021; 144: 7-19Crossref PubMed Scopus (30) Google Scholar2021 An International, Multicentred Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome20Adler A. Novelli V. Amin A.S. Abiusi E. Care M. Nannenberg E.A. et al.An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome.Circulation. 2020; 141: 418-428Crossref PubMed Scopus (96) Google Scholar2020 Reappraisal of Reported Genes for Sudden Arrhythmic Death: An Evidence-Based Evaluation of Gene Validity for Brugada Syndrome21Hosseini S.M. Kim R. Udupa S. Costain G. Jobling R. Liston E. et al.National Institutes of Health Clinical Genome Resource ConsortiumReappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome.Circulation. 2018; 138: 1195-1205Crossref PubMed Scopus (149) Google Scholar2018 Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes10Ingles J. Goldstein J. Thaxton C. Caleshu C. Corty E.W. Crowley S.B. et al.Evaluating the clinical validity of hypertrophic cardiomyopathy genes.Circ Genom Precis Med. 2019; 12e002460Crossref Scopus (131) Google Scholar2017 Open table in a new tab Table 3Definitions and abbreviationsTerm (abbreviation)DefinitionSudden cardiac arrest (SCA)Sudden cessation of cardiac activity with haemodynamic collapse, typically due to sustained ventricular arrhythmiaSudden cardiac death (SCD)Death that occurs within 1 h of onset of symptoms in witnessed cases, and within 24 h of last being seen alive when it is unwitnessedSudden unexplained death (syndrome) [SUD(S)]Unexplained sudden death occurring in an individual older than 1 yearSudden unexplained death in infancy (SUDI)aSynonymous with ‘sudden unexplained infant death’ (SUID).Unexplained sudden death occurring in an individual younger than 1 year with negative pathological and toxicological assessmentSudden arrhythmic death (syndrome) [SAD(S)]bSynonymous with ‘autopsy-negative sudden unexplained death’.Unexplained sudden death occurring in an individual older than 1 year with negative pathological and toxicological assessmentAbbreviationASOAllele-specific oligonucleotideACMGAmerican College of Medical Genetics & GenomicsaCGHArray comparative genomic hybridizationACMArrhythmogenic cardiomyopathyALVCArrhythmogenic left ventricular cardiomyopathyARVCArrhythmogenic right ventricular cardiomyopathyAFibAtrial fibrillationASDAtrial septal defectASSAtrial stand stillADAutosomal dominantARAutosomal recessiveBrSBrugada syndromeCRDSCalcium release deficiency syndromeCCDCardiac conduction diseaseRyR2Cardiac ryanodine receptorCMRCardiovascular magnetic resonanceCPVTCatecholaminergic polymorphic ventricular tachycardiaCVSChorionic villous sampleCMAChromosomal microarrayCHDCongenital heart diseaseCNVCopy number variantDCMDilated cardiomyopathyERPEarly repolarization patternECAExtracardiac anomalyGWASGenome-wide association studiesGRSGenomic risk scoresHCMHypertrophic cardio-myopathyIVFIdiopathic ventricular fibrillationICDImplantable cardioverter-defibrillatorICCInherited cardiovascular conditionsJLNSJervell and Lange-Nielsen SyndromeLCSDLeft cardiac sympathetic denervationLVLeft ventricularLVHLeft ventricular hypertrophyLVNCLeft ventricular non-compaction cardiomyopathyLBLikely BenignLP/PLikely pathogenic/pathogenicLQTSLong QT syndromeMAFMinor allele frequencyMLPAMultiplex ligation-dependent probe amplificationNGSNext-generation sequencingPRSPolygenic risk scoresPCRPolymerase chain reactionPNPPolyneuropathyPCCDProgressive cardiac conduction diseaseRCMRestrictive cardiomyopathysiRNAShort interfering RNASQTSShort QT syndromeSNPSingle-nucleotide polymorphismSNVSingle-nucleotide variantSNDSinus node dysfunctionSCASudden cardiac arrestSCDSudden cardiac deathTOFTetralogy of FallotTdPTorsades de pointesTKOSTriadin knockout syndromeUCAUnexplained cardiac arrestUTRsUntranslated regionsVUSVariants of uncertain clinical significanceVFVentricular fibrillationVSDventricular septal defectWESWhole-exome sequencingWGSWhole-genome sequencingWPWWolff–Parkinson–White syndromeX-chrX-chromosomala Synonymous with ‘sudden unexplained infant death’ (SUID).b Synonymous with ‘autopsy-negative sudden unexplained death’. Open table in a new tab Research conducted, over the last three decades, has provided considerable insights into the modes of inheritance of cardiovascular disorders and into the underlying genes and pathways. These insights were fuelled by developments in technologies for DNA sequencing and genotyping, statistical genetic approaches, and our increased understanding of the wide spectrum of genetic variation in the general population. Two broad categories of cardiovascular disorders are recognized: Mendelian disorders that are caused by the inheritance of one or two genetic variants and that typically cluster in families, and disorders with complex inheritance, wherein multiple genetic variants contribute and for which familial clustering is less pronounced. In both categories non-genetic factors also contribute to the ultimate phenotypic expression. Inheritance patterns for monogenic disorders include autosomal dominant (AD), autosomal recessive (AR), and sex-linked. In AD disorders, the inheritance of a single defective copy of a gene, either the maternal or the paternal copy, is sufficient to cause the disorder. In some cases, an AD condition may result from a de novo variant in the gene and occurs in individuals with no history of the disorder in their family. In AR disorders, both the maternal and paternal copies need to be defective to produce the disorder. X-linked disorders are caused by pathogenic variants in genes on the X chromosome. Two types of X-linked disorders are recognized, X-linked dominant and X-linked recessive. In females with an X-linked dominant condition, a pathogenic variant in one of the two copies of the gene is sufficient to cause the condition. In males, who have only one X chromosome, a pathogenic variant in the only copy of the gene causes the disorder. In X-linked recessive inheritance, in males, one defective copy of the gene is sufficient to cause the condition, whereas females are mildy affected or unaffected if only one copy of the gene is aberrant. A characteristic of both types of X-linked inheritance is that males cannot pass on the disorder to their sons. Besides Mendelian inheritance, single-gene disorders may exhibit mitochondrial inheritance. Because mitochondrial DNA is inherited from the mother, only females can pass on genetic defects residing on mitochondrial DNA. In rare cases, disease-causing variants may arise post-zygotically (during development), leading to mosaicism (the occurrence of genetically distinct cell populations). Mosaicism may be limited to somatic cells, where there would be no risk of passing the disease-variant to the offspring, or it may also affect the germ line cell population and in this way the disease variant may be passed to the offspring. Disease-associated genetic variants likely lie on a spectrum of population frequency and phenotype effect size. Mendelian variants, when dominant, are usually characterized by an ultra-low minor allele frequency (MAF, typically <0.01%) in the population and have large effect sizes (Figure 1). Classically, genes underlying Mendelian disorders were identified by linkage studies that tracked chromosomal regions that are co-inherited with the condition in multiple affected individuals in families, followed by Sanger sequencing of the linked chromosomal interval. More recently, next-generation sequencing (NGS) and WES have been successful in identifying novel genes underlying Mendelian disorders. It is estimated that there are about 7000 single-gene inherited disorders of which causative genes have been discovered for over 4000.23Claussnitzer M. Cho J.H. Collins R. Cox N.J. Dermitzakis E.T. Hurles M.E. et al.A brief history of human disease genetics.Nature. 2020; 577: 179-189Crossref PubMed Scopus (140) Google Scholar Accordingly, many genes for hereditary cardiomyopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic cardiomyopathy (ACM); hereditary arrhythmias, such as LQTSs, Brugada syndrome (BrS), short QT syndromes (SQTSs), and CPVT; and cardiac conduction defects have been identified.24Roberts R. Marian A.J. Dandona S. Stewart A.F. Genomics in cardiovascular disease.J Am Coll Cardiol. 2013; 61: 2029-2037Crossref PubMed Scopus (0) Google Scholar In Mendelian cardiovascular disorders with potentially devastating initial manifestations, such as SCD or aortic dissection, appropriate and prompt identification of individuals at risk is imperative.25Kim L. Devereux R.B. Basson C.T. Impact of genetic insights into mendelian disease on cardiovascular clinical practice.Circulation. 2011; 123: 544-550Crossref PubMed Scopus (5) Google Scholar Genetic testing has been recommended for a number of inherited cardiac conditions for several years and has become a standard aspect of clinical management in affected families. The primary benefit of genetic testing is to identify at-risk carriers of the familial pathogenic variant (and non-carriers who are unlikely to develop disease) through cascade screening, assuming a genetic variant is identified that can be predicted with confidence to cause the disease. Such clinical genetic testing for these single-gene disorders has been shown to be cost-effective26Wordsworth S. Leal J. Blair E. Legood R. Thomson K. Seller A. et al.DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.Eur Heart J. 2010; 31: 926-935Crossref PubMed Scopus (104) Google Scholar and can be considered as a success story in the application of genetics into clinical practice. Although pathogenic Mendelian genetic variants are characterized by a large effect size, they may not in isolation be sufficient to yield a disease phenotype. This is evidenced by incomplete disease penetrance where only a proportion of individuals in the same family carrying a particular genetic variant shows the disease. Another feature that characterizes Mendelian disorders is the phenomenon of variable expressivity, where different disease severity is observed among individuals carrying the same underlying genetic predisposition. What this means is that, even within pedigrees sharing the same pathogenic variant, the clinical presentation can vary from a patient having no clinical manifestation of the disease to another having severe disease. A clearly pathogenic variant can, therefore, have high diagnostic value, but low prognostic utility.27Wilde A.A. Behr E.R. Genetic testing for inherited cardiac disease.Nat Rev Cardiol. 2013; 10: 571-583Crossref PubMed Scopus (117) Google Scholar Besides non-genetic (such as environmental) factors, penetrance and expressivity of Mendelian genetic defects are influenced by the co-inheritance of other genetic factors alongside the Mendelian genetic defect, that act to exacerbate or attenuate the effect of the latter on the phenotype (often referred to as ‘genetic modifiers’, Figure 1). Contrary to Mendelian disorders, where a single large-effect variant primarily determines susceptibility to the disorder, susceptibility to disorders with complex inheritance rests on the co-inheritance of multiple variants. Such variants are identified by means of genome-wide association studies (GWAS) that compare the prevalence of millions of genetic variants genome-wide between affected individuals and controls. Non-Mendelian genetic risk variants that contribute to cardiovascular disease risk and that are detectable with current approaches and study sample sizes can be broadly grouped into two categories. These comprise common variants, typically defined as having a MAF of >1–5%, which have individually small effect sizes, and intermediate effect variants (MAF <1–2%) with effect sizes and frequencies between common and Mendelian variants (Figure 1). It is likely that a continuum of genetic complexity exists where at one end of the spectrum are Mendelian disorders determined primarily by the inheritance of an ultra-rare large-effect genetic defect, and at the other end are highly polygenic disorders determined by many genetic variants with additive effect (Figure 1). While some disorders present primarily with one form of inheritance, different inheritance patterns may exist for the same disorder.28Lahrouchi N. Tadros R. Crotti L. Mizusawa Y. Postema P.G. Beekman L. et al.Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome.Circulation. 2020; 142: 324-338Crossref PubMed Scopus (30) Google Scholar Emerging data suggest that common variants of small effect and intermediate effect variants may, to varying extents, influence penetrance in individuals with Mendelian genetic defects by pushing the genetic burden towards the threshold of disease, as well as influence severity of disease.29Tadros R. Francis C. Xu X. Vermeer A.M.C. Harper A.R. Huurman R. et al.Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect.Nat Genet. 2021; 53: 128-134Crossref PubMed Scopus (45) Google Scholar,30Harper A.R. Goel A. Grace C. Thomson K.L. Petersen S.E. Xu X. et al.HCMR InvestigatorsCommon genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.Nat Genet. 2021; 53: 135-142Crossref PubMed Scopus (42) Google Scholar While their incorporation into genetic testing approaches is expected to increase the sensitivity of genetic testing, the identification of such modulatory variants is still a matter of intense research and therefore currently not clinically applicable. Genomic technology has enabled efficient and comprehensive assessment of genetic variation within individuals. We each carry millions of variants in our genome, ranging in size from substitutions of a single-nucleotide (single-nucleotide variant; SNV, sometimes termed SNP) to deletions or duplications of an entire chromosome. Smaller variants, such as SNVs, are more prevalent in our genomes. We each carry about 100 SNVs that have arisen de novo during our development and are private to us,31Conrad D.F. Keebler J.E. DePristo M.A. Lindsay S.J. Zhang Y. Casals F. et al.1000 Genomes ProjectVariation in genome-wide mutation rates within and between human families.Nat Genet. 2011; 43: 712-714Crossref PubMed Scopus (375) Google Scholar and thousands of other rare SNVs.32Abecasis G.R. Altshuler D. Auton A. Brooks L.D. Durbin R.M. Gibbs R.A. et al.1000 Genomes Project ConsortiumA map of human genome variation from population-scale sequencing.Nature. 2010; 467: 1061-1073Crossref PubMed Scopus (5763) Google Scholar The largest structural variants are much less prevalent, for example aneuploidy (the presence of an abnormal number of chromosomes in a cell), affects about 1 in 300 live births.33Hassold T. Hunt P. To err (meiotically) is human: the genesis of human aneuploidy.Nat Rev Genet. 2001; 2: 280-291Crossref PubMed Scopus (1690) Google Scholar Though individually smaller variants are less likely to cause disease than larger changes that are more likely to disrupt genome function, collectively they probably account for the majority of phenotypic variability and inherited disease.34Stranger B.E. Forrest M.S